{"pmid": "8964276", "sentences": {"sent_1": {"Section": "METHODS", "text": "A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy .", "entities": {"entity_1": {"text": "lamotrigine", "class": "Intervention", "negation": 0, "UMLS": "", "start": 7}, "entity_2": {"text": "carbamazepine", "class": "Intervention", "negation": 0, "UMLS": "", "start": 9}, "attribute_1": {"text": "newly diagnosed", "class": "modifier", "negation": 0, "UMLS": "", "start": 15}, "attribute_2": {"text": "recurrent", "class": "modifier", "negation": 0, "UMLS": "", "start": 18}, "entity_3": {"text": "epilepsy", "class": "Participant", "negation": 0, "UMLS": "", "start": 19}}, "relations": {}}, "sent_2": {"Section": "METHODS", "text": "The efficacy and safety of lamotrigine and carbamazepine as monotherapy in patients with untreated , newly diagnosed or recurrent partial and/or generalised tonic-clonic seizures , were compared in a randomised", "entities": {"entity_4": {"text": "efficacy", "class": "Outcome", "negation": 0, "UMLS": "", "start": 1}, "entity_5": {"text": "safety", "class": "Outcome", "negation": 0, "UMLS": "", "start": 3}, "entity_6": {"text": "lamotrigine", "class": "Intervention", "negation": 0, "UMLS": "", "start": 5}, "entity_7": {"text": "carbamazepine", "class": "Intervention", "negation": 0, "UMLS": "", "start": 7}, "attribute_3": {"text": "untreated", "class": "modifier", "negation": 0, "UMLS": "", "start": 13}, "attribute_4": {"text": "newly diagnosed", "class": "modifier", "negation": 0, "UMLS": "", "start": 15}, "attribute_5": {"text": "recurrent", "class": "modifier", "negation": 0, "UMLS": "", "start": 18}, "attribute_6": {"text": "partial", "class": "modifier", "negation": 0, "UMLS": "", "start": 19}, "attribute_7": {"text": "seizures", "class": "modifier", "negation": 0, "UMLS": "", "start": 23}, "entity_8": {"text": ", were", "class": "Participant", "negation": 0, "UMLS": "", "start": 24}}, "relations": {}}, "sent_3": {"Section": "METHODS", "text": ", open , multicentre study .", "entities": {}, "relations": {}}, "sent_4": {"Section": "METHODS", "text": "Patients received 24 weeks ' treatment with oral lamotrigine 100 mg ( LTG 100 , n = 115 ) or 200 mg ( LTG 200 , n = 111 )", "entities": {"entity_9": {"text": "oral", "class": "Intervention", "negation": 0, "UMLS": "", "start": 7}, "entity_10": {"text": "lamotrigine", "class": "Intervention", "negation": 0, "UMLS": "", "start": 8}, "attribute_8": {"text": "100 mg", "class": "measure", "negation": 0, "UMLS": "", "start": 9}, "entity_11": {"text": "LTG 100", "class": "Intervention", "negation": 0, "UMLS": "", "start": 12}, "attribute_9": {"text": "200 mg", "class": "measure", "negation": 0, "UMLS": "", "start": 20}, "entity_12": {"text": "LTG 200", "class": "Intervention", "negation": 0, "UMLS": "", "start": 23}}, "relations": {}}, "sent_5": {"Section": "METHODS", "text": "or carbamazepine 600 mg ( CBZ 600 , n = 117 ) .", "entities": {"entity_13": {"text": "carbamazepine", "class": "Intervention", "negation": 0, "UMLS": "", "start": 1}, "attribute_10": {"text": "600 mg", "class": "measure", "negation": 0, "UMLS": "", "start": 2}, "entity_14": {"text": "CBZ 600", "class": "Intervention", "negation": 0, "UMLS": "", "start": 5}}, "relations": {}}, "sent_6": {"Section": "METHODS", "text": "Efficacy measurements were comparable between the three treatment groups , although the higher lamotrigine dose was possibly most effective , with 60.4 % completing seizure free compared with 51.3 %", "entities": {"entity_15": {"text": "Efficacy measurements", "class": "Outcome", "negation": 0, "UMLS": "", "start": 0}, "attribute_11": {"text": "higher", "class": "modifier", "negation": 0, "UMLS": "", "start": 12}, "entity_16": {"text": "lamotrigine", "class": "Intervention", "negation": 0, "UMLS": "", "start": 13}, "attribute_12": {"text": "effective", "class": "modifier", "negation": 0, "UMLS": "", "start": 18}, "attribute_13": {"text": "60.4 %", "class": "measure", "negation": 0, "UMLS": "", "start": 21}, "entity_17": {"text": "seizure free", "class": "Outcome", "negation": 0, "UMLS": "", "start": 24}, "attribute_14": {"text": "51.3 %", "class": "measure", "negation": 0, "UMLS": "", "start": 28}}, "relations": {}}, "sent_7": {"Section": "METHODS", "text": "( LTG 100 ) and 54.7 % ( CBZ 600 ) .", "entities": {"entity_18": {"text": "LTG 100", "class": "Intervention", "negation": 0, "UMLS": "", "start": 1}, "attribute_15": {"text": "54.7 %", "class": "measure", "negation": 0, "UMLS": "", "start": 5}, "entity_19": {"text": "CBZ 600", "class": "Intervention", "negation": 0, "UMLS": "", "start": 8}}, "relations": {}}, "sent_8": {"Section": "METHODS", "text": "Both dosage regimens of lamotrigine were well tolerated .", "entities": {"entity_20": {"text": "lamotrigine", "class": "Intervention", "negation": 0, "UMLS": "", "start": 4}, "attribute_16": {"text": "well tolerated", "class": "modifier", "negation": 0, "UMLS": "", "start": 6}}, "relations": {}}, "sent_9": {"Section": "METHODS", "text": "More patients on CBZ 600 reported adverse experiences , 66 % versus 53 % ( LTG 100 ) and 58 % ( LTG 200 ) , and of these a", "entities": {"entity_21": {"text": "CBZ 600", "class": "Intervention", "negation": 0, "UMLS": "", "start": 3}, "entity_22": {"text": "adverse experiences", "class": "Outcome", "negation": 0, "UMLS": "", "start": 6}, "attribute_17": {"text": "66 %", "class": "measure", "negation": 0, "UMLS": "", "start": 9}, "attribute_18": {"text": "53 %", "class": "measure", "negation": 0, "UMLS": "", "start": 12}, "entity_23": {"text": "LTG 100", "class": "Intervention", "negation": 0, "UMLS": "", "start": 15}, "attribute_19": {"text": "58 %", "class": "measure", "negation": 0, "UMLS": "", "start": 19}, "entity_24": {"text": "LTG 200", "class": "Intervention", "negation": 0, "UMLS": "", "start": 22}}, "relations": {}}, "sent_10": {"Section": "METHODS", "text": "greater proportion were attributed to CBZ 600 treatment , 53 % versus 23 % ( LTG 100 ) and 28 % ( LTG 200 ) .", "entities": {"entity_25": {"text": "CBZ 600", "class": "Intervention", "negation": 0, "UMLS": "", "start": 5}, "attribute_20": {"text": "53 %", "class": "measure", "negation": 0, "UMLS": "", "start": 9}, "attribute_21": {"text": "23 %", "class": "measure", "negation": 0, "UMLS": "", "start": 12}, "entity_26": {"text": "LTG 100", "class": "Intervention", "negation": 0, "UMLS": "", "start": 15}, "attribute_22": {"text": "28 %", "class": "measure", "negation": 0, "UMLS": "", "start": 19}, "entity_27": {"text": "LTG 200", "class": "Intervention", "negation": 0, "UMLS": "", "start": 22}}, "relations": {}}, "sent_11": {"Section": "METHODS", "text": "Similarly , a greater proportion of the CBZ 600 group required a change in dose , 47 % versus 20 % ( LTG 100 ) and 17 % ( LTG", "entities": {"entity_28": {"text": "CBZ 600", "class": "Intervention", "negation": 0, "UMLS": "", "start": 7}, "attribute_23": {"text": "change in dose", "class": "modifier", "negation": 0, "UMLS": "", "start": 12}, "attribute_24": {"text": "47 %", "class": "measure", "negation": 0, "UMLS": "", "start": 16}, "attribute_25": {"text": "20 %", "class": "measure", "negation": 0, "UMLS": "", "start": 19}, "entity_29": {"text": "LTG 100", "class": "Intervention", "negation": 0, "UMLS": "", "start": 22}, "attribute_26": {"text": "17 %", "class": "measure", "negation": 0, "UMLS": "", "start": 26}}, "relations": {}}, "sent_12": {"Section": "METHODS", "text": "200 ) or withdrew completely due to adverse experiences , 10.3 % versus 4.3 % ( LTG 100 ) and 4.5 % ( LTG 200 ) .", "entities": {"entity_30": {"text": "200", "class": "Intervention", "negation": 0, "UMLS": "", "start": 0}, "entity_31": {"text": "withdrew", "class": "Outcome", "negation": 0, "UMLS": "", "start": 3}, "entity_32": {"text": "adverse experiences", "class": "Outcome", "negation": 0, "UMLS": "", "start": 7}, "attribute_27": {"text": "10.3 %", "class": "measure", "negation": 0, "UMLS": "", "start": 10}, "attribute_28": {"text": "4.3 %", "class": "measure", "negation": 0, "UMLS": "", "start": 13}, "entity_33": {"text": "LTG 100", "class": "Intervention", "negation": 0, "UMLS": "", "start": 16}, "attribute_29": {"text": "4.5 %", "class": "measure", "negation": 0, "UMLS": "", "start": 20}, "entity_34": {"text": "LTG 200", "class": "Intervention", "negation": 0, "UMLS": "", "start": 23}}, "relations": {}}, "sent_13": {"Section": "METHODS", "text": "The most common adverse experience leading to withdrawal was rash , with approximately double the proportion of reports occurring in patients on CBZ 600 ( 5.1 % ) compared with", "entities": {"attribute_30": {"text": "most common", "class": "modifier", "negation": 0, "UMLS": "", "start": 1}, "entity_35": {"text": "adverse experience", "class": "Outcome", "negation": 0, "UMLS": "", "start": 3}, "entity_36": {"text": "withdrawal", "class": "Outcome", "negation": 0, "UMLS": "", "start": 7}, "entity_37": {"text": "rash", "class": "Outcome", "negation": 0, "UMLS": "", "start": 9}, "entity_38": {"text": "CBZ 600", "class": "Intervention", "negation": 0, "UMLS": "", "start": 22}, "attribute_31": {"text": "5.1 %", "class": "measure", "negation": 0, "UMLS": "", "start": 25}}, "relations": {}}, "sent_14": {"Section": "METHODS", "text": "lamotrigine ( 1.7 % on LTG 100 and 2.7 % on LTG 200 ) .", "entities": {"entity_39": {"text": "lamotrigine", "class": "Intervention", "negation": 0, "UMLS": "", "start": 0}, "attribute_32": {"text": "1.7 %", "class": "measure", "negation": 0, "UMLS": "", "start": 2}, "entity_40": {"text": "LTG 100", "class": "Intervention", "negation": 0, "UMLS": "", "start": 5}, "attribute_33": {"text": "2.7 %", "class": "measure", "negation": 0, "UMLS": "", "start": 8}, "entity_41": {"text": "LTG 200", "class": "Intervention", "negation": 0, "UMLS": "", "start": 11}}, "relations": {}}, "sent_15": {"Section": "METHODS", "text": "Overall lamotrigine appeared equally effective but better tolerated compared with carbamazepine .", "entities": {"entity_42": {"text": "lamotrigine", "class": "Intervention", "negation": 0, "UMLS": "", "start": 1}, "attribute_34": {"text": "equally effective", "class": "modifier", "negation": 0, "UMLS": "", "start": 3}, "attribute_35": {"text": "better tolerated", "class": "modifier", "negation": 0, "UMLS": "", "start": 6}, "entity_43": {"text": "carbamazepine", "class": "Intervention", "negation": 0, "UMLS": "", "start": 10}}, "relations": {}}}}